奥氮平会使帕金森症恶化。 - Suppr

Suppr

超能文献

Olanzapine can worsen parkinsonism.

作者信息

Jiménez-Jiménez F J, Tallón-Barranco A, Ortí-Pareja M, Zurdo M, Porta J, Molina J A

机构信息

Department of Neurology, Hospital Príncipe de Asturias, Universidad de Alcalá de Henares, Madrid, Spain.

出版信息

Neurology. 1998 Apr;50(4):1183-4. doi: 10.1212/wnl.50.4.1183-a.

DOI:10.1212/wnl.50.4.1183-a

PMID:9566425

Abstract

摘要

相似文献

Olanzapine can worsen parkinsonism.

Neurology. 1998 Apr;50(4):1183-4. doi: 10.1212/wnl.50.4.1183-a.

Olanzapine and neuroleptic malignant syndrome.

Psychosomatics. 2002 Nov-Dec;43(6):505-6; author reply 506. doi: 10.1176/appi.psy.43.6.505.

Olanzapine: extrapyramidal side effects in the elderly.

Aust N Z J Med. 1999 Jun;29(3):371-2. doi: 10.1111/j.1445-5994.1999.tb00722.x.

The economic consequences of a drug-drug interaction.

J Clin Psychopharmacol. 2001 Feb;21(1):119-20. doi: 10.1097/00004714-200102000-00027.

Worsening of motor features of parkinsonism with olanzapine.

Mov Disord. 1999 Nov;14(6):1014-6. doi: 10.1002/1531-8257(199911)14:6<1014::aid-mds1017>3.0.co;2-9.

Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.

Eur Psychiatry. 1999 Oct;14(6):356-7. doi: 10.1016/s0924-9338(99)00153-4.

Interaction between olanzapine and haloperidol.

J Clin Psychopharmacol. 1999 Jun;19(3):272-3. doi: 10.1097/00004714-199906000-00013.

Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.

Neurol Sci. 2000 Aug;21(4):209-15. doi: 10.1007/s100720070078.

Olanzapine usage associated with neuroleptic malignant syndrome.

Psychosomatics. 2001 Nov-Dec;42(6):528-9. doi: 10.1176/appi.psy.42.6.528.

Olanzapine/risperidone and diabetes risk.

J Clin Psychiatry. 2003 Jul;64(7):847-8; author reply 848. doi: 10.4088/jcp.v64n0718a.

引用本文的文献

Current and Future Neuropharmacological Options for the Treatment of Essential Tremor.

Curr Neuropharmacol. 2020;18(6):518-537. doi: 10.2174/1570159X18666200124145743.

Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.

Curr Psychiatry Rep. 2018 Jan 27;20(1):3. doi: 10.1007/s11920-018-0869-z.

A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease.

F1000Res. 2013 Jul 9;2:150. doi: 10.12688/f1000research.2-150.v1. eCollection 2013.

Treatment of the special patient with schizophrenia.

Dialogues Clin Neurosci. 2001 Jun;3(2):123-35. doi: 10.31887/DCNS.2001.3.2/rrconley.

The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview.

J Neurol. 2006 Feb;253(2):171-5. doi: 10.1007/s00415-005-0943-4. Epub 2005 Aug 17.

Novel Antipsychotics in the Treatment of Behavioral Disturbances and Psychoses Associated With Neurodegenerative Disorders.

Prim Care Companion J Clin Psychiatry. 2000 Jun;2(3):80-88. doi: 10.4088/pcc.v02n0302.

Treatment of psychosis in Parkinson's disease: safety considerations.

Drug Saf. 2003;26(9):643-59. doi: 10.2165/00002018-200326090-00004.

Parkinson's disease: the treatment of drug-induced hallucinations and psychosis.

Curr Neurol Neurosci Rep. 2001 Jul;1(4):320-8. doi: 10.1007/s11910-001-0085-8.

Antipsychotic medications and the elderly: effects on cognition and implications for use.

Drugs Aging. 2001;18(1):45-61. doi: 10.2165/00002512-200118010-00004.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Olanzapine can worsen parkinsonism.

Neurology. 1998 Apr;50(4):1183-4. doi: 10.1212/wnl.50.4.1183-a.

Olanzapine and neuroleptic malignant syndrome.

Psychosomatics. 2002 Nov-Dec;43(6):505-6; author reply 506. doi: 10.1176/appi.psy.43.6.505.

Olanzapine: extrapyramidal side effects in the elderly.

Aust N Z J Med. 1999 Jun;29(3):371-2. doi: 10.1111/j.1445-5994.1999.tb00722.x.

The economic consequences of a drug-drug interaction.

J Clin Psychopharmacol. 2001 Feb;21(1):119-20. doi: 10.1097/00004714-200102000-00027.

Worsening of motor features of parkinsonism with olanzapine.

Mov Disord. 1999 Nov;14(6):1014-6. doi: 10.1002/1531-8257(199911)14:6<1014::aid-mds1017>3.0.co;2-9.

Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.

Eur Psychiatry. 1999 Oct;14(6):356-7. doi: 10.1016/s0924-9338(99)00153-4.

Interaction between olanzapine and haloperidol.

J Clin Psychopharmacol. 1999 Jun;19(3):272-3. doi: 10.1097/00004714-199906000-00013.

Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.

Neurol Sci. 2000 Aug;21(4):209-15. doi: 10.1007/s100720070078.

Olanzapine usage associated with neuroleptic malignant syndrome.

Psychosomatics. 2001 Nov-Dec;42(6):528-9. doi: 10.1176/appi.psy.42.6.528.

Olanzapine/risperidone and diabetes risk.

J Clin Psychiatry. 2003 Jul;64(7):847-8; author reply 848. doi: 10.4088/jcp.v64n0718a.

引用本文的文献

Current and Future Neuropharmacological Options for the Treatment of Essential Tremor.

Curr Neuropharmacol. 2020;18(6):518-537. doi: 10.2174/1570159X18666200124145743.

Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.

Curr Psychiatry Rep. 2018 Jan 27;20(1):3. doi: 10.1007/s11920-018-0869-z.

A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease.

F1000Res. 2013 Jul 9;2:150. doi: 10.12688/f1000research.2-150.v1. eCollection 2013.

Treatment of the special patient with schizophrenia.

Dialogues Clin Neurosci. 2001 Jun;3(2):123-35. doi: 10.31887/DCNS.2001.3.2/rrconley.

The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview.

J Neurol. 2006 Feb;253(2):171-5. doi: 10.1007/s00415-005-0943-4. Epub 2005 Aug 17.

Novel Antipsychotics in the Treatment of Behavioral Disturbances and Psychoses Associated With Neurodegenerative Disorders.

Prim Care Companion J Clin Psychiatry. 2000 Jun;2(3):80-88. doi: 10.4088/pcc.v02n0302.

Treatment of psychosis in Parkinson's disease: safety considerations.

Drug Saf. 2003;26(9):643-59. doi: 10.2165/00002018-200326090-00004.

Parkinson's disease: the treatment of drug-induced hallucinations and psychosis.

Curr Neurol Neurosci Rep. 2001 Jul;1(4):320-8. doi: 10.1007/s11910-001-0085-8.

Antipsychotic medications and the elderly: effects on cognition and implications for use.

Drugs Aging. 2001;18(1):45-61. doi: 10.2165/00002512-200118010-00004.